Zacks SCR

$VNRX: Reimbursement pathway in France in place for future sales of Nu.Q Cancer & Nu.Q NETs assays under CE Mark. Watching to see if the company achieved 2025 cash neutrality. Papers, posters & conference presentations continue to build the evidence base buff.ly/nRx9KnM

$NIVF: Doubling Down on UAE Real Estate Project #HealthTechInvesting #FertilityTech #biotech buff.ly/gMTn9FD

$DEFTF 4Q25 Earnings Preview: Ongoing Crypto Market Weakness #technology #crypto #digitalassets #ETF #ETP buff.ly/uvZXp01

$CVKD @OTCMarkets Hosts Virtual Investor Presentation with Quang Pham, Chairman and CEO of Cadrenal Therapeutics, and @DavidBautz, PhD, Senior Analyst at Zacks SCR buff.ly/sBFmkfc

$FBLG: Phase 1/2 Data in Diabetic Foot Ulcers Expected Before End of 2026 #Fibroblasts #RegenerativeMedicine buff.ly/YvGAfly

$HCTI: 4Q25 Earnings Preview #DigitalHealthInnovation #HealthTech buff.ly/Ufeq5xh

$CDRF: Additional Details for CRDF-005 #Oncology #ClinicalTrials #CancerResearch buff.ly/tu5715A

$CCLD: 4Q25 Earnings Review – Building Earnings Power and FCF #technology #healthcare #healthcaretech buff.ly/NcuxEn1

$CING: @CingulateInc Laying the Foundation for 1H:27 Launch buff.ly/XqUXlXB by @vanjohn10

$RERE: Consistent Execution with Several Catalysts That Could Drive Upside to Estimates #technology #recycling #preowned buff.ly/UTns1wr

$MFI 2H25 Earnings Preview #FintechAsia #AITradingSolutions #LiquidityInnovation buff.ly/sVfraTi

$NIVF: 4Q25 Earnings Preview #HealthTechInvesting #FertilityTech #biotech buff.ly/6x9wmWc

$LGVN Receives Cash Infusion #biotech #celltherapy #biotherapeutics buff.ly/H1qAAg6

$NSRX: 4Q:26 Start for Pivotal Study #BiotechInnovation #ClinicalTrials #NextGenTherapeutics buff.ly/2JwU7PX

$MTVA @OTCMarkets Hosts Virtual Investor Presentation with H.H. Kim, CEO and President of MetaVia, and @DavidBautz, PhD, Senior Analyst at Zacks SCR buff.ly/jhPHhsc

$LFLRF: LaFleur Minerals publishes positive economic plan for gold production in Abitibi mining camp #GoldExploration #MiningInnovation #CriticalMetals buff.ly/XHkAsC9

$MRDN: Prioritizing expansion into new regulated markets buff.ly/Rhum06w

$GXAI: @Gaxos_Labs Beats Forecasts as Both Businesses Outperform buff.ly/h4tL2zj by @LTommy256

$CXW: Reactivating idled facilities adds capacity to meet ICE’s growing needs #smallcap #investing #stockmarket #stocks buff.ly/mL0ECeH

$SNGX: Interim Readout for Phase 3 CTCL Trial in 2Q26 #biotech #lymphoma #CTCL buff.ly/XpjledW